Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Cash & Equivalents (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Cash & Equivalents for 7 consecutive years, with $45.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 36.16% to $45.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.4 million through Dec 2025, down 36.16% year-over-year, with the annual reading at $45.4 million for FY2025, 36.16% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $45.4 million at Pliant Therapeutics, down from $93.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $114.3 million in Q1 2024, with the low at $25.1 million in Q2 2022.
  • Average Cash & Equivalents over 5 years is $63.0 million, with a median of $56.3 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents plummeted 80.28% in 2021, then surged 215.03% in 2023.
  • Over 5 years, Cash & Equivalents stood at $51.7 million in 2021, then tumbled by 34.8% to $33.7 million in 2022, then skyrocketed by 87.72% to $63.2 million in 2023, then rose by 12.58% to $71.2 million in 2024, then plummeted by 36.16% to $45.4 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $45.4 million, $93.7 million, and $86.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.